187223-15-0 Usage
Uses
Used in Pharmaceutical Industry:
FMOC-L-HYP(BOM)-OH is used as a building block in solid-phase peptide synthesis for the preparation of complex peptides and peptidomimetics. Its role is crucial for the selective and controlled addition of the L-hydroxyproline residue, which is essential for the synthesis of peptides with specific biological activities and therapeutic properties.
Used in Research and Development:
In the research and development sector, FMOC-L-HYP(BOM)-OH is employed as a key component in the synthesis of novel peptide-based drugs and for studying the structure-activity relationships of peptides. Its use enables scientists to explore the potential of new peptide sequences for various applications, including drug discovery and the development of diagnostic tools.
Used in Peptide Synthesis Education:
FMOC-L-HYP(BOM)-OH is also utilized as an educational tool in academic settings, where it helps students understand the principles of solid-phase peptide synthesis and the importance of protecting groups in the synthesis of complex peptide structures. This knowledge is fundamental for students pursuing careers in biochemistry, medicinal chemistry, and related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 187223-15-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,7,2,2 and 3 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 187223-15:
(8*1)+(7*8)+(6*7)+(5*2)+(4*2)+(3*3)+(2*1)+(1*5)=140
140 % 10 = 0
So 187223-15-0 is a valid CAS Registry Number.
InChI:InChI=1/C28H33N3O8/c1-28(2,3)39-26(35)30-13-12-29-25(34)38-17-14-23(24(32)33)31(15-17)27(36)37-16-22-20-10-6-4-8-18(20)19-9-5-7-11-21(19)22/h4-11,17,22-23H,12-16H2,1-3H3,(H,29,34)(H,30,35)(H,32,33)/t17-,23+/m1/s1
187223-15-0Relevant academic research and scientific papers
CYCLOHEXAPEPTIDES AS SELECTIVE SOMATOSTATIN SST5 RECEPTOR AGONISTS
-
Page/Page column 35, (2020/05/19)
The disclosures herein relate to novel compounds of formula (1) : (1) and salts thereof, wherein W, X, Y, Z, m, n, q, R1, R2, R3, R4, R5 and R6 are defined herein, and their use in treating
NOVEL PROCESS FOR THE PREPARATION OF PASIREOTIDE
-
Page/Page column 24, (2017/01/09)
The present invention relates to a novel process for the preparation of Pasireotide of formula 11 [Cyclo [Phe-{4-(OCO-NH-CH2-CH2-NH2)) Pro}-Phg-DTrp-Lys-Tyr(Bzl)]]. The invention also relates to a novel intermediate compound of formula 8 and process thereof which is used for preparation of compound of formula 11.
PROCESS FOR PEPTIDE SYNTHESIS OF PEPTIDES CONTAINING A 4-HYDROXY-PROLINE SUBSTRUCTURE
-
Page 19-20, (2008/06/13)
The present invention relates to processes for preparing peptides and to intermediates involved in such processes, e.g. a process for preparing a compound of formula (VIII) wherein R12 and R13 are as defined herein.
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential
Lewis, Ian,Bauer, Wilfried,Albert, Rainer,Chandramouli, Nagarajan,Pless, Janos,Weckbecker, Gisbert,Bruns, Christian
, p. 2334 - 2344 (2007/10/03)
A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery o
